πŸ‡ΊπŸ‡Έ FDA
Patent

US 11406716

Modified RNAi agents

granted A61KA61K48/00A61P

Quick answer

US patent 11406716 (Modified RNAi agents) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K48/00, A61P, A61P31/12, A61P31/18